Pfizer (NYSE: PFE) stock jumped 3.1% through 11:20 a.m. ET Monday morning in response to a Wall Street Journal article over ...

Medifast, Inc. MED is making significant strides in adapting to the evolving healthcare landscape with the growing ...

Whilst it can work as an affective weight-loss drug for those who are obese, it should never be used for a short-term ...

With a new patent settlement, generic partners Mylan and Natco have cleared one hurdle to a potential U.S. launch of their ...

The drug, initially intended for use by diabetics, has soared in popularity as a result of the weight-loss effects.

Scholar Rock is also working on a treatment that helps preserve lean muscle that is often lost during rapid weight loss by patients taking the new class of GLP-1 drugs. Scholar Rock's stock is down 45 ...

As you are likely aware, many people are using a class of drugs called GLP-1 receptor agonists for weight loss. One of the ...

Scholar Rock said on Monday its experimental drug apitegromab met the main goal of a late-stage trial in patients with a type of rare genetic disease, sending the company's shares surging in premarket ...

After psychological side effects doomed the first generation of cannabinoid receptor 1–targeting drugs for weight loss, Novo ...

"It's very, very clear that physician spending is not the problem in healthcare." -- Jen Brull, MD, president of the American ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Today, DexCom is the leading CGM company, with an estimated 40% market share. Importantly, CGM products are relatively nascent. DexCom generates nearly $4 billion in annual sales on a user base of ...